Ya disponibles las comunicaciones GETECCU que serán presentadas en la ECCO 2024 divididas por tipo de comunicación:

Comunicaciones orales

OP37 Effect of the HLA-DQA1*05 allele on the efficacy of ustekinumab in patients with Crohn’s Disease. Multicenter study based on the ENEIDA registry of GETECCU.

J. Guardiola Capón

Abstract citation ID: jjad212.0037

DOP60 Prevalence of undiagnosed inflammatory Bowel Disease in patients with spondyloarthritis: EISER Study

A. Gutiérrez Casbas

Abstract citation ID: jjad212.0100

DOP75 Frequency and effectiveness of dose escalation of biologic therapy in Inflammatory Bowel Disease: The RAINBOW-IBD study of ENEIDA

C. Rubín De Célix

Abstract citation ID: jjad212.0115

DOP80 Prevalence and factors associated with Inflammatory Bowel Disease (IBD) activity during pregnancy: updated data from the DUMBO Registry

M. Chaparro

Abstract citation ID: jjad212.0120

Póster

P230 Clinical characteristics, risk factors and management of patients with inflammatory bowel disease and hidradenitis suppurativa: a nationwide multicenter study of the GETECCU ENEIDA registry.

L. Madero Velázquez

Abstract citation ID: jjad212.0360

P419 Proximal Crohn’s disease location is associated with a more benign course of perianal Crohn’s disease (the PERIAPROX study)

C. Romero-Mascarell

Abstract citation ID: jjad212.0549

P516 Subcutaneous infliximab cut-off points in a large cohort of Spanish patients with inflammatory bowel disease and factors associated with long-term outcomes.

M. Iborra

Abstract citation ID: jjad212.0646

P655 The ileorectal anastomosis after a total colectomy is a feasible and valid surgical alternative in the treatment of inflammatory bowel disease

I. Tapiolas

Abstract citation ID: jjad212.0785

P817 Incidence and risk factors of infection in patients with inflammatory bowel disease: longitudinal prospective INFEII registry of GETECCU

Y. Zabana

Abstract citation ID: jjad212.0947

P855 Have biological agents changed the need for abdominal surgery in inflammatory bowel disease over time?

C. Suria

Abstract citation ID: jjad212.0985

P987 Impact of Crohn’s Disease Location on Biologic Therapy Persistence and the Risk of Intestinal Surgery: Insights from the ENEIDA Registry (the DISCOLOC Study)

A. Giordano

Abstract citation ID: jjad212.1117

P1115 Characteristics and management of pyoderma gangrenosum and erythema nodosum in patients with inflammatory bowel disease: PIONOSO multicenter study

I. Rodríguez-Lago

Abstract citation ID: jjad212.1245

P989 Switching from intravenous to subcutaneous vedolizumab in patients with inflammatory bowel disease in clinical remission: a multicenter study from GETECCU

B. Gros

Abstract citation ID: jjad212.1119

P1170 Long-term outcomes of newly diagnosed Inflammatory Bowel Disease (IBD) patients: results from the nationwide EpidemIBD study of GETECCU

M. Chaparro

Abstract citation ID: jjad212.1300

P211 Impact of celiac disease on the outcome of Inflammatory Bowel Disease

I. Alonso

Abstract citation ID: jjad212.0341

P676 Unveiling the impact on in utero exposure to biologic treatments for inflammatory bowel disease (IBD) on children’s psychomotor development: Insights from the DUMBO registry of GETECCU

L.M. Palomino Pérez

Abstract citation ID: jjad212.0806

P822 Therapeutic Management And Risk Of Colectomy In Patients With Acute Severe Ulcerative Colitis And Previous Exposure To Anti-Tnf Drugs. A Cohort Study Of Geteccu

F. Mesonero Gismero

Abstract citation ID: jjad212.0952

P949 Effectiveness and safety of rectal tacrolimus in patients with ulcerative colitis. TACRO-TOPIC study. A multicenter study from the young group of GETECCU

E. Fuentes-Valenzuela

Abstract citation ID: jjad212.1079

P829 Clostridioides difficile infection in patients using vedolizumab and antiTNF: incidence and consequences (CDIFVEDO study of GETECCU)

M. Gonzalez Vivo

Abstract citation ID: jjad212.0959